The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

There is ample epidemiologic evidence for an association of chronic hepatitis C virus (HCV)
infection with B-cell non-Hodgkin lymphoma (B-NHL). B-NHL subtypes most frequently …

Viral hepatitis affects millions of people worldwide, and host immunity is the key determinant
of patient outcome. Viral hepatitis can be life threatening in patients with haematological …

Hepatitis C virus (HCV) reactivation in patients receiving cancer treatment has been
reported in retrospective studies. We sought to determine prospectively the incidence …

Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as
well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent and …

BACKGROUND & AIMS: Data on acute exacerbation and reactivation of chronic hepatitis C
virus (HCV) infection following chemotherapy are very limited. We sought to characterize the …

Infectious agents, such as HCV, account for∼ 15% of human cancers. HCV infects not only
hepatocytes but also extrahepatic cells. Chronic HCV infection can induce chronic …

HCV chronic infection is characterized by possible development of both hepatic and
extrahepatic manifestations. The infection by this both hepatotropic and lymphotropic virus is …

Hepatitis C virus (HCV) infection increases the risk of B‐cell non‐Hodgkin lymphomas (B‐
NHL). Antiviral treatment (AT) can induce hematological responses in patients with marginal …

Background International guidelines suggest hepatitis C virus (HCV) eradication by direct‐
acting antivirals (DAAs) after first‐line immunochemotherapy (I‐CT) in patients with HCV …